Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy

被引：22
作者：
Huang, Zhao-Hui [1 ,2 ]
Hua, Dong [1 ]
Li, Li-Hua [1 ]
Zhu, Jing-De [2 ]
机构：
[1] Suzhou Univ, Affiliated Hosp 4, Wuxi Oncol Inst, Wuxi 214062, Jiangsu Prov, Peoples R China
[2] Fudan Univ, State Key Lab Oncogenes & Related Genes, Shanghai Canc Inst, Coll Med, Shanghai 200032, Peoples R China
来源：
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY | 2008年 / 134卷 / 10期
关键词：
gastric cancer; chemotherapy; polymorphism; P53; protein; 5-fluorouracil; apoptosis;
D O I：
10.1007/s00432-008-0380-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Objective The polymorphism of p53 codon 72 (Arg72Pro) has been suggested to play an important role in many cancers and may influence the response to chemotherapy. Our aim was to investigate the association of p53 Arg72Pro polymorphism with the clinical outcome of gastric cancer patients treated with 5-FU-based adjuvant chemotherapy. Methods The p53 codon 72 genotype was determined in blood samples from 110 Chinese patients with gastric cancer treated with 5-fluorouracil (5-FU)-based adjuvant chemotherapy, using polymerase chain reaction-ligation detection reaction (PCR-LDR) method. Results Kaplan-Meier survival analysis showed that gastric cancer patients with Pro/Pro genotype had shorter relapse-free survival (chi(2) = 10.632, P = 0.005) and overall survival (chi(2) = 7.104, P = 0.029) than patients with other genotypes. Cox multivariate analysis showed that Pro/Pro genotype was associated with statistically significant reduced relapse-free survival (adjusted OR = 3.049, 95% CI: 1.363-6.819, P = 0.007) and overall survival (adjusted OR = 2.581, 95% CI: 1.052-6.330, P = 0.038). Conclusion These results suggested that p53 codon 72 polymorphism appears to be an independent prognostic factor in gastric cancer patients treated with 5-FU-based adjuvant chemotherapy.
引用
收藏
页码：1129 / 1134
页数：6
相关论文
共 35 条
[1]   Genetic status of p53 in stomach cancer: Somatic mutations and polymorphism of codon 72 [J].
Belyavskaya, V. A. ;
Vardosanidze, V. K. ;
Smirnova, O. Yu. ;
Karakin, E. I. ;
Savkin, I. V. ;
Gervas, P. A. ;
Cherdyntseva, N. V. ;
Voevoda, M. I. .
BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2006, 141 (02) :243-246
[2]   p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis [J].
Bergamaschi, D ;
Gasco, M ;
Hiller, L ;
Sullivan, A ;
Syed, N ;
Trigiante, G ;
Yulug, I ;
Merlano, M ;
Numico, G ;
Comino, A ;
Attard, M ;
Reelfs, O ;
Gusterson, B ;
Bell, AK ;
Heath, V ;
Tavassoli, M ;
Farrell, PJ ;
Smith, P ;
Lu, X ;
Crook, T .
CANCER CELL, 2003, 3 (04) :387-402
[3]   Adjuvant therapy of resected gastric cancer is necessary [J].
Carrato, A ;
Gallego-Plazas, J ;
Guillen-Ponce, C .
SEMINARS IN ONCOLOGY, 2005, 32 (06) :S105-S108
[4]   The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil [J].
Diasio, RB ;
Johnson, MR .
PHARMACOLOGY, 2000, 61 (03) :199-203
[5]   The codon 72 polymorphic variants of p53 have markedly different apoptotic potential [J].
Dumont, P ;
Leu, JIJ ;
Della Pietra, AC ;
George, DL ;
Murphy, M .
NATURE GENETICS, 2003, 33 (03) :357-365
[6]   Common polymorphisms in TP53 and MDM2 and the relationship to TP53 mutations and clinical outcomes in women with ovarian and peritoneal carcinomas [J].
Galic, Vijaya ;
Willner, Julia ;
Wollan, Melissa ;
Garg, Ruchi ;
Garcia, Rochelle ;
Goff, Barbara A. ;
Gray, Heidi J. ;
Swisher, Elizabeth M. .
GENES CHROMOSOMES & CANCER, 2007, 46 (03) :239-247
[7]   Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS) - novel predictors for response and survival in gastric cancer patients [J].
Goekkurt, E ;
Hoehn, S ;
Wolschke, C ;
Wittmer, C ;
Stueber, C ;
Hossfeld, DK ;
Stoehlmacher, J .
BRITISH JOURNAL OF CANCER, 2006, 94 (02) :281-286
[8]   Postoperative chemotherapy for gastric cancer [J].
Hejna, Michael ;
Wohrer, Stefan ;
Schmidinger, Manuela ;
Raderer, Markus .
ONCOLOGIST, 2006, 11 (02) :136-145
[9]   Prediction of clinical outcome of fluoropyrimidine-based chemotherapy for gastric cancer patients, in terms of the 5-fluorouracil metabolic pathway [J].
Ichikawa W. .
Gastric Cancer, 2006, 9 (3) :145-155
[10]  
Ishida Y, 2002, ANTICANCER RES, V22, P2805
1234